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Abstract 
Given  the  large-scale  deployment  of  Electronic 
Health Records (EHR), secondary use of EHR data 
will  be  increasingly  needed  in  all  kinds  of  health 
services or clinical research. This paper reports some 
data  quality  issues  we  encountered  in  a  survival 
analysis  of  pancreatic  cancer  patients.  Using  the 
clinical  data  warehouse  at  Columbia  University 
Medical Center in the City of New York, we mined 
EHR data elements collected between 1999 and 2009 
for a cohort of pancreatic cancer patients.  Of the 
3068  patients  who  had  ICD-9-CM  diagnoses  for 
pancreatic  cancer,  only  1589  had  corresponding 
disease  documentation  in  pathology  reports. 
Incompleteness  was  the  leading  data  quality  issue; 
many study variables had missing values to various 
degrees. Inaccuracy and inconsistency were the next 
common  problems.  In  this  paper,  we  present  the 
manifestations  of  these  data  quality  issues  and 
discuss  some  strategies  for  using  emerging 
informatics technologies to solve these problems. 
Introduction 
Electronic  health  records  (EHR)  have  become  a 
pervasive  healthcare  information  technology.  They 
replaced  paper-based  systems  in  many  healthcare 
organizations  and  garnered  rich  health  data,  which 
hold great value for reuse. As The American Medical 
Informatics Association (AMIA) stated at its website, 
(http://www2.amia.org/inside/initiatives/healthdata/): 
“Secondary  use  of  health  data  can  enhance 
healthcare  experiences  for  individuals,  expand 
knowledge about disease and appropriate treatments, 
strengthen understanding about the effectiveness and 
efficiency of our healthcare systems, support public 
health  and  security  goals,  and  aid  businesses  in 
meeting the needs of their customers”. Retrospective 
analysis  of  health  data  holds  promise  to  expedite 
scientific  discovery  in  medicine  and  constitutes  a 
significant  part  of  clinical  research.  Currently, 
secondary use of clinical data is still at its early stage 
[1].    National  initiatives  have  been  created  to 
facilitate  widening  use  of  EHR  to  support  clinical 
research in the United States [2].   
This  paper  reports  our  first-hand  experience  with 
some data quality issues in a survival analysis study 
for  pancreatic  cancer.  We  first  describe  our  data 
source  and  methods  for  case  identification  and 
research  variable  extraction.    Then  we  identify  the 
major data quality issues and their manifestations. We 
discuss  the  potential  applications  of  the  emerging 
health informatics technologies to mitigate these data 
quality issues. 
Data Source and Methods 
The  Columbia  University  Medical  Center’s  clinical 
data  warehouse  is  the  data  source  of  this  study 
(http://ctcc.cpmc.columbia.edu/rdb/index.html).  This 
warehouse has been in operation since 1994 and has 
accumulated health data for more than 2.7 million of 
patients seen at The NewYork Presbyterian Hospital. 
Since  2002,  a  comprehensive  controlled  clinical 
vocabulary  called  the  Medical  Entities  Dictionary 
(http://med.dmi.columbia.edu/)  has  been  used  to 
integrate  data  of  various  semantic  representations 
from heterogeneous hospital information systems for 
the clinical data warehouse. Our 3-step procedure to 
identify  the  cases  of  pancreatic  cancer  in  our  data 
warehouse is described as follows: 
Step  1.  We  used  the  9
th  version  of  International 
Classification  of  Diseases,  Clinical  Modification 
(ICD-9-CM)  and  its  codes  corresponding  to  the 
“malignant  neoplasm  of  pancreas”  (157.0-157.9)  to 
identify all the patients with ICD-9 diagnoses during 
the  period  of  (01//01/1999-01/30/2009).  The 
pathology  reports,  radiology  reports,  clinical  notes, 
laboratory tests, discharge summaries, as well as the 
drug registry and administrative files were extracted 
for further analysis. 
Step 2. We queried the pathology reports to exclude 
patients  who  did  not  have  adequate  documentation 
about  pancreatic  cancer  diagnoses  in  the  reports. 
Initially, we applied an SQL query using variations of 
‘pancreas’  key  term;  subsequently,  we  manually 
reviewed  the  query  output  to  either  exclude  non-
malignancies or  filter out pancreatic tumors that were 
not diagnosed as primary lesions. 
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for  endocrine  and  exocrine  neoplasms.  Each  group 
was further classified by disease subtype standards, 
e.g. the WHO Classification of Epithelial Tumors of 
the Exocrine Pancreas. 
After identifying a cohort of patients with pancreatic 
cancer,  we  manually  abstracted  and  automatically 
extracted  specific  pathologic  characteristics  from 
these  patients’  pathology  reports,  such  as  the  size, 
location,  and  differentiation  of  tumors,  lymph node 
metastasis,  as  well  as  the  specifications  of  related 
health  conditions  such  as  chronic  pancreatitis. 
Various EHR data elements were reviewed to collect 
other  study  variables.    For  example,  we  abstracted 
information  about  metastasis  at  diagnosis  and 
progression  of  disease  from  radiology  reports.  We 
abstracted  personal  medical  history, personal habits 
(e.g., smoking and alcohol consumption), as well as 
family medical history from clinical notes. We also 
queried laboratory tests tables to extract biochemistry 
at diagnosis (aspartate aminotransferase-AST, alanine 
aminotransferase-ALT,  alkaline  phosphatase-ALP, 
albumin,  total  bilirubin)  and  tumor  markers 
preoperatively  (CA19-9,  carcinoembryonic  antigen-
CEA).  Furthermore,  we  used  the  drug  registry  to 
extract  chemotherapy  regimens  and  used 
administrative  files  to  extract  patient  demographics 
(e.g., birth date, gender, race and ethnicity).  Also, 
discharge  summaries  and  hospitalization  archives 
served as an extra data source for filling the missing 
values  of  the  aforementioned  study  variables.  The 
tumor  stage  for  all  the  patients  was  manually 
annotated using standard parameters. Manual review 
of the free text patient information was performed to 
ensure  the  accuracy  of  information  extraction.  We 
also applied the three common measurements of data 
quality, as specified below: 
Incompleteness – missing information;  
Inconsistency  –  information  mismatch  between 
various or within the same EHR data source;  
Inaccuracy  –  non-specific,  non-standards-based, 
inexact, incorrect, or imprecise information. 
Descriptive  statistics  for  incompleteness  and 
qualitative  observations  for  the  other  two 
measurements are presented below. The results of the 
extraction/abstraction process fed both the calculation 
of descriptive statistics and the formation of specific 
observations. Particularly, the discrepancies between 
or within the various EHR elements (measurement of 
inconsistency)  were  identified  by  matching  the 
extraction/abstraction  output  from  two  sources  (or 
within the same source) for a single parameter and a 
number  of randomly selected patients e.g. the SQL 
query  output  in  the  drug  registry  and  the  manual 
review  of  clinical  notes  for  chemotherapy  regimen 
were compared. 
Results 
Using  the  ICD-9-CM  codes  for  pancreatic 
malignancies  (157.0-157.9),  3068  patients  were 
identified in the CUMC clinical data warehouse for 
the  reported  period  (01/01/1999  –  01/30/2009). 
However,  after  querying  the  pathology  reports  for 
these patients, we found that 1479 (48%) patients did 
not  have  corresponding  diagnoses  or  disease 
documentation in the pathology reports. Among the 
remaining 1589 (52%) patients, incompleteness in the 
key study variables that define the disease stage (e.g. 
tumor  size  and  extension  beyond  pancreas,  lymph 
node  and  distant  metastasis  for  exocrine  tumors) 
further reduced the size of our cohort to 522 (17%) 
patients, which included 98 patients with endocrine 
pancreatic  cancer,  218  with early stage (resectable) 
exocrine pancreatic ductal adenocarcinoma and 206 
with  late  stage  exocrine  pancreatic  ductal 
adenocarcinoma
1.  Significant  information 
incompleteness  was  observed  in  many  of  the  study 
variables  so  that  variables  of  more  than  50% 
incompleteness were excluded from further analysis. 
For  example,  incompleteness  of  family  history  of 
cancer for exocrine pancreatic adenocarcinomas was 
56%  and  52%  for  the  early  and  late  stage 
respectively.  Table  1a  and  1b  show  the  degree  of 
incompleteness  (=  the  percentage  of  patients  with 
incomplete information in each group of our cohort) 
for the study variables of the survival analysis. For 
endocrine pancreatic tumors (Table 1a), the degree of 
information  incompleteness  was  between  0%  (age, 
gender,  functional  status  and  surgery)  and  44% 
(tumor markers). The degree of incompleteness was 
higher  in  the  later  stage  ductal  adenocarcinomas 
(Table  1b),  with  many  of  the  selected  variables 
having more than 50% missing values. 
The  values  of  some  study  variables  had  to  be 
manually inferred by combining extracted data from 
various EHR data sources. For example, disease stage 
and progression are two indispensible variables in a 
survival analysis, but both of them were not explicitly 
documented  in  the  EHR  and  had  to  be  manually 
inferred  from  other  key  variables.  Even  if  disease 
progression  was  documented,  often  the  information 
was  not  explicitly  available  and  required  backward 
                                                            
1 The selection was based on the AJCC TNM system and 
the WHO classification system criteria for the exocrine and 
the endocrine pancreatic tumors correspondingly. 
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radiology  reports  using  deep  knowledge  of  the 
international  standards  and  guidelines  for  defining 
disease  stage  and  disease progression. Moreover, it 
was  difficult  to  define  time  parameters  for  certain 
events, e.g. the timing of disease progression.  As an 
important characteristic of dynamic patient phenotype 
and a crucial factor in survival analysis, temporality 
was often not captured accurately. Except for “time to 
critical event” (e.g., death or censoring) and “date of 
diagnosis”, which were commonly documented in a 
straightforward manner, it was difficult to determine 
the exact period for medical interventions or events, 
e.g. the duration of chemotherapy treatments. 
Table 1a – Degree of incompleteness for some of the 
study variables for the endocrine pancreatic tumors 
Variables  Endocrine 
Necrosis  20% 
Number of Mitoses  21% 
Lymph Node Metastasis  28% 
Perineural/Lymphovascular Invasion  15% 
Differentiation  38% 
Size  6% 
Chronic Pancreatitis  14% 
Smoking- Alcohol  27%-29% 
History of Other Cancer  35% 
Family History of Cancer  39% 
Tumor Markers  46% 
 
Table 1b – Contrast of degrees of incompleteness for 
some of the study variables between the early and 
late stage ductal adenocarcinomas  
Variables  Early  Late 
Lymph Node Metastasis  1%  88% 
Differentiation  3%  49% 
Localization  0%  76% 
Tumor Size  2%  86% 
Smoking- Alcohol  37%-41%  46%-48% 
Chronic Pancreatitis  0%  92% 
History of Other Cancer  17%  28% 
Biochemistry Labs  6%-9%  13%-23% 
Tumor Markers  24%  29%-35% 
Chemotherapy  0%  26% 
Family History of Cancer  56%  52% 
 
We  also  observed  that  information  inconsistency 
occurred either between different EHR data sources 
or within the same EHR data source. For example, 
some chemotherapy regimens were documented in the 
clinical notes but not in the drug registry. However, 
there  was  evidence  that  the  patient  was  treated 
exclusively in our institution so that their treatment 
information  should  be  documented  in  the  drug 
registry.  Also,  in  a  few  cases,  pancreatitis  was 
diagnosed as being chronic in the pathology reports 
but was reported as being only acute in the clinical 
notes.  Such  inconsistencies  across  different  data 
sources  revealed  multiple  inconsistent  entries  about 
the same health problem in different components of 
the  EHR,  which  could  be  made  by  the  same  or 
different  clinician(s).  Uncoordinated  or  redundant 
data entries into different data sources in EHR could 
not  only  cause  information  discrepancies  but  also 
form big barriers to selecting reliable data sources for 
secondary use of EHR data. Furthermore, information 
inconsistency within the same data source was also 
observed.  Some patients received two different ICD-
9-CM  codes  for  their  diagnoses  of  diabetes,  both 
250.01 and 250.02 for type-1 and type-2 respectively. 
Information inaccuracy was also frequently observed. 
It was reflected as poor granularity of the diagnosis 
terms or disease classification codes and inadequate 
or non-standardized documentation of disease status 
or treatment details. Consequently, such information 
could not satisfy the information needs of a survival 
analysis study. For example, the non-specific ICD-9-
CM code for diabetes (250 for diabetes mellitus) was 
often used.  Also, the patient treatment plan was often 
sketchy with inadequate temporal information. Some 
study variables (e.g., chemotherapy cycles) were hard 
to  infer  because  of  the  inaccuracy  of  the  base 
variables (e.g., chemotherapy treatment information). 
Furthermore,  in  some  patient  cases,  the  endocrine 
tumor grade was also not defined following the WHO 
classification system guidelines.  
The above problems can be exacerbated since EHR 
users tend to copy and paste information [3], which 
can propagate the errors.  
Discussion 
Semantic  representational  variations  among  data 
collected  by  different  EHR  systems  are  typical  in 
many  healthcare  organizations.  A  clinical  data 
warehouse  aggregates  data  and  greatly  facilitates 
retrospective  analysis  and  data  mining  [4].  The 
Columbia  University  clinical  data  warehouse 
equipped with the MED demonstrates the value of a 
comprehensive  controlled  clinical  vocabulary  for 
integrating  heterogeneous  data.    The  current  study 
would  be  impossible  without  this  valuable  data 
resource.  The  issues  we  described  above,  i.e., 
3information  incompleteness,  inaccuracy,  and 
inconsistency, are not unique to our data warehouse, 
but are common challenges for many institutions. 
It could be argued that a weakness of our study is the 
lack  of  descriptive  statistics  for  inconsistency  and 
inaccuracy; however, this is not a simple task since 
there are many aspects for consideration. If we further 
analyzed the example of chemotherapy regimen that 
was mentioned above, we would have observed that 
there were various ways of registering drugs in EHR, 
i.e.  using:  (1)  the  trade  drug  name  (e.g.  Gemzar-
Taxotere, in clinical notes), (2) the main compound 
name (e.g. Gemcitabine-Docetaxel, in drug registry), 
(3)  an  acronym  substituting  the  drug  names  (e.g. 
GTX,  mainly  in  clinical  notes).  To  accurately  and 
fully  check  the  inconsistencies  could  be  a  project 
itself.  Similarly,  inaccuracy  measurement  would 
require an extensive chart review of each patient case, 
a  rather  cumbersome  process.  Considering  the 
aforementioned  we  decided  to  provide  some 
qualitative examples only. 
Within a clinical data warehouse, to reduce the health 
data that is unavailable, inaccessible or incomputable, 
new technology for storage (e.g. for radiology data) 
and  new  methods  for  natural  language  processing 
(e.g.  for  symptoms  or  signs  recorded  on  free-text 
formats) are needed. Various approaches have been 
suggested for mining clinical data warehouses, such 
as an extended Structured Query Language (SQL) for 
manipulating  groups  of  records  [5]  or  text  mining 
tools  for  the  natural  language  processing  of  the 
pathology reports [6]. It should be mentioned though 
that text mining tools cannot achieve 100% accuracy. 
Similarly, SQL queries can only assist the researcher 
in  accomplishing  part  of  the  tasks,  as  in  our  study 
where  SQL  queries  had  to  be  combined  with 
laborious  manual  scrutiny  of  disease-specific 
information.  Therefore,  we  suggest  combining 
dedicated  text  mining  tools  and  special  post 
processing  to  facilitate  information  retrieval.  A 
dedicated  text-mining  tool  should  be  based  on  a 
source- and domain-specific lexicon. For example, in 
our case study, the pathology reports could be mined 
using  a  lexicon  that  includes  the  appropriate 
pathology  terms  for  pancreatic  cancer;  this  lexicon 
should  be  also  adjustable  to  support  the  mining  of 
other  types  of  notes.  Post  processing  queries  could 
further filter the outcomes and aggregate the values 
for the disease variables of interest. 
Beyond any solutions that may improve the accuracy 
of information extraction, strategies for improving the 
quality  of  collected  data  are  much  needed  as  well. 
Some  solutions  were  mentioned  above  (e.g.,  new 
tools,  better  classification  systems,  etc.);  however, 
their success demands considerable user involvement. 
The  lessons  learned  from  projects  that linked EHR 
with  clinical  research  databases  might  offer  better 
insight to a more efficient research data capture [7].  
The  discrepancies  of  the  diagnoses  for  pancreatic 
cancer  between  the  ICD-9-CM  codes  and  the 
pathology notes could be attributed to two possible 
reasons: (a) information fragmentation – e.g., some 
patients had been initially treated elsewhere so that 
our  institution  did  not  have  the  longitudinal  health 
records for this subset of transferring patients; and (b) 
lack of contextual information in structured disease 
diagnoses  –  e.g.,  for  some  patients,  the  pancreatic 
tumor  was  not  primary  but  metastatic,  while 
pathology reports only captured information for the 
primary  tumors.  The  latter  case  reveals  a  problem 
currently  associated  with  the  ICD-9-CM  coding 
system,  which  is  that  its  classification  cannot 
distinguish primary from metastatic tumors. 
The  varying  degrees  of  information  incompleteness 
between  the  early  and  late  stage  ductal 
adenocarcinomas  (Table  1b)  indicated  that  EHR 
probably captures less information for patients with 
terminal  diseases  than  for  patients  with  less  severe 
diseases.  It  is  likely  that  severe  patients  might  be 
transferred to dedicated cancer treatment centers so 
that their information was not captured in our EHR. 
As aforementioned, this information fragmentation is 
a big cause for information incompleteness. 
Incompleteness caused by information fragmentation 
of  the  healthcare  systems  (i.e.,  patients  moving 
between  multiple  healthcare  entities  for  special 
referrals  or  emergency  healthcare,  with  each  entity 
holding partial health records for the patients) could 
be mitigated using health information exchange (HIE) 
methods  that  support  information  federation  across 
multiple  healthcare  entities.  More  national  and 
regional health information exchange networks with 
broad  connectivity  among  EHR  systems  should  be 
further developed to improve patient data flow across 
different healthcare entities. 
Information  incompleteness  due  to  poor 
documentation  could  be  attributed  to  both  patients 
and  healthcare  providers  who  did  not  report  or 
document critical information, e.g. family history or 
personal habits. In the case of survival analyses, this 
may  be  handled  by  the  appropriate  imputation 
methods that fill in the missing values for a set of pre-
defined variables. However, other solutions should be 
applied.    To  date,  secondary  use  of  EHR  data  is 
largely  focused  on  ad-hoc  data  extraction  support, 
rather than on proactive documentation support that 
4improves  the  comprehensiveness  of  health  data 
upfront. Next, we describe how emerging informatics 
technologies such as personal health records (PHR) 
and clinical registries could offer potential solutions. 
PHR are a new form of health records for engaging 
individual  patients  to  control  access  to  their  own 
health  information  [8].  Besides  the  support  for 
enhanced  patients-caregiver  communications,  PHR 
could also be a potential solution to many data quality 
issues.  For  example,  information  such  as  personal 
habits that was rather incomplete in our study is less 
likely  to  be  recorded  by  physicians  compared  to 
urgent  medical  conditions  in  a  limited  patient 
encounter  time  window.  Unambiguously,  the 
implementation  and  adoption  of  PHR  raise  various 
issues  such  as  data  confidentiality  and  security, 
usability and user acceptance, and so forth; all these 
can  be  barriers  to  the  uses  of  PHR  and  should  be 
considered. 
Clinical registries are another promising technology 
to  improve  data quality. A clinical registry collects 
data for a specific group of patients, e.g. patients with 
pancreatic cancer, has a predefined format and can be 
easily designed to interoperate with EHR system and 
hence  to  support  patient  information  exchange  and 
federation. 
An alternative to address information incompleteness 
problem is to define “standard content” for EHR. To 
our knowledge, there is no community agreed-upon 
“essential content for EHR” or standard common data 
elements  for  EHR.    It  is  unknown  how  much 
information is truly sufficient or needed at the point 
of  care  for  diagnostic  decision  making  and  what 
information is mostly important for physicians during 
the  limited  patient  visit  time.  For  example,  “lymph 
node  metastasis”  is  practically  unimportant  for  late 
stage  ductal  adenocarcinomas  given  that  patients 
classified in this group will not survive long; this is 
probably the reason that tumor size was missing in 
86%  of  the  late  stage  cases.  Answers  to  these 
questions can help doctors to better spare their time 
for entering only important and necessary data. These 
are  open  biomedical  informatics  research  questions 
that have the potential to improve the efficiency of 
EHR  data  and  alleviate  documentation  burdens,  as 
well as to reduce redundancy caused by “copy-paste” 
errors.    More  standards  for  clinical  documentation 
should be developed to address this problem. 
Conclusion 
PHR,  clinical  registry,  and  health  information 
exchange  will  be  the key enabling technologies for 
improving  EHR  data  quality  toward  longitudinal 
health  records.  With  more  and  more  institutions 
maturing in clinical data warehousing, the next step is 
to  develop  new  methods  for  clinical  analytics. 
Advanced  or  automatic data validation and flexible 
data presentation tools should be developed to ensure 
information  integrity.  Effective  strategies  for 
secondary  use  of  EHR  data  could  also  be 
accumulated  from  case  studies  and  shared  with  the 
research community as the best practices. 
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